Literature DB >> 20479551

Pulmonary metastasis from renal synovial sarcoma treated by stereotactic body radiotherapy: a case report and review of the literature.

Tejinder Kataria1, Nandigam Janardhan, Ashu Abhishek, Gautam K Sharan, Swarupa Mitra.   

Abstract

Primary synovial sarcoma of kidney is an uncommon neoplasm, metastasizing most commonly to lung. Surgery and/or palliative chemotherapy for pulmonary metastases is commonly used to improve tumor control and survival. Stereotactic body radiotherapy (SBRT) is a relatively new approach to treat pulmonary metastasis, encouraged by the results of cranial and spinal stereotactic radiosurgery. The local control and toxicity profile of patients with pulmonary metastasis treated with SBRT are comparable to pulmonary metastatectomy. Furthermore, with advancement of imaging techniques, immobilization techniques, tumor-tracking techniques, and treatment planning and delivery system, SBRT can now be alternatively employed for the treatment of pulmonary metastasis as a comparable substitute to surgical resection.

Entities:  

Mesh:

Year:  2010        PMID: 20479551     DOI: 10.4103/0973-1482.63551

Source DB:  PubMed          Journal:  J Cancer Res Ther        ISSN: 1998-4138            Impact factor:   1.805


  3 in total

1.  Primary Renal Synovial Sarcoma and Clinical and Pathological Findings: a Systematic Review.

Authors:  Leandro Blas; Javier Roberti
Journal:  Curr Urol Rep       Date:  2021-03-11       Impact factor: 3.092

2.  Primary synovial sarcoma of kidney: a rare differential diagnosis of renomegaly.

Authors:  Gaurang Modi; Irappa Madabhavi; Harsha Panchal; Asha Anand; Apurva Patel; Sonia Parikh; Swaroop Revannasiddaiah
Journal:  Case Rep Pathol       Date:  2014-12-24

Review 3.  Primary synovial sarcoma of the kidney: a case report of complete pathological response at a Lebanese tertiary care center.

Authors:  Alissar El Chediak; Deborah Mukherji; Sally Temraz; Samer Nassif; Sara Sinno; Rami Mahfouz; Ali Shamseddine
Journal:  BMC Urol       Date:  2018-05-11       Impact factor: 2.264

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.